introduction since emergence end infection severe acute respiratory syndrome coronavirus sars-cov-2 leading coronavirus disease covid-19 major threat health people around world april sars-cov-2 officially infected million people worldwide resulting million registered death disease course covid-19 vary widely asymptomatic mild infection moderate severe critical case severe pneumonia sometimes evolving acute respiratory distress syndrome ards due excessive inflammation lymphocytopenia considerable risk fatality several risk factor associated increased risk mortality including male sex advanced age comorbidities diabetes obesity asthma addition heterogeneity clinical outcome influenced host immune response sars-cov-2 infection individual infected sars-cov-2 produce immunoglobulin igg iga antibody viral spike protein nucleocapsid protein within week symptom onset remain elevated following initial viral clearance protein contains receptor binding domain rbd mediates binding human angiotensin-converting enzyme ace2 receptor identified receptor sars-cov-2 viral entry currently available evidence suggests increased antibody level correlated increased clinical disease severity hand anti-sars-cov-2 antibody titer shown strongly correlated vitro virus neutralization despite well-established relationship antibody response sars-cov-2 severity association mortality still unclear higher serum igm level correlated higher mortality rate severe/critical covid-19 patient whereas study showed lower antibody level linked increased mortality besides generation adaptive immune response sars-cov-2 infection trigger innate immune response characterized production cytokine severe covid-19-associated ards known cytokine storm aggressive inflammatory response high-level release cytokine important driver disease progression death early pandemic already became clear circulating level numerous inflammatory cytokine interleukin -1β il-8 il-6 il-10 tumor necrosis factor tnf interferon ifn -γ-inducible protein ip-10 granulocyte macrophage-colony stimulating factor gm-csf monocyte chemoattractant protein-1 mcp-1 increased patient sars-cov-2 infection among pro-inflammatory cytokine il-6 considered key mediator cytokine response upon covid-19 infection il-6 level found important predictor covid-19 severity play pivotal role high mortality rate addition il-6 also il-1β il-2 tnf-α ip-10 gm-csf mcp-1 anti-inflammatory cytokine il-10 found correlate disease severity class cytokine received extra attention covid-19 pandemic interferon ifns essential antiviral cytokine serving first line immune defence viral infection however date conflicting evidence interferon response sars-cov-2 infection reported recent study showed patient severe covid-19 defective ifn response however study showed increased prolonged production ifns patient infected sars-cov-2 turn correlated negative clinical outcome order address question large multi-centre cohort study set-up collect blood sample hospitalized covid-19 patient first wave covid-19 pandemic thoroughly profile immune response analysing sars-cov-2-specific antibody panel cytokine baseline next association early immune response clinical outcome laboratory parameter determined result patient demographic clinical characteristic clinical outcome retrospective cross-sectional study performed using blood sample covid-19 patient hospitalized first covid-19 wave april june systematic covid-19 pcr screening performed hospital admission regardless reason hospitalization blood sample collected baseline defined within day positive pcr antibody detection within day positive pcr cytokine measurement demographic disease characteristic comorbidities baseline reported table covid-19 patient categorized according classification criterion clinical management covid-19 interim guidance issued may table mild/asymptomatic moderate severe critically ill disease category patient information regarding disease category baseline blood sampling lacking median iqr age patient 71,0 year 57,0–81,8 56.5 men median iqr bmi 27.7 24.3–31.2 table significant difference age found different disease severity category 0.1877 statistically significant difference found sex significantly higher number male patient critically ill group moderate group compared patient group asymptomatic/mild category baseline 0.0156 0.0001 respectively bmi significantly different different disease severity category 0.0282 significantly higher bmi severe group compared asymptomatic/mild group 0.0192 common comorbidities arterial hypertension patient 42.8 diabetes patient 18.8 kidney injury patient 17.2 malignancy patient 12.2 table next difference laboratory parameter disease severity investigated focussing difference patient mild moderate severe disease category critically ill group among laboratory parameter found baseline acute phase reactant c-reactive protein crp ferritin level significantly different critically ill patient compared patient within moderate 0.0001 0.0074 respectively mild disease category 0.0001 0.0003 respectively specifically critically ill patient displayed higher crp ferritin level furthermore white blood cell count significantly different critically ill patient compared patient belonging moderate disease category 0.0199 critically ill patient displaying higher white blood cell count significant difference found level coagulation dysfunction marker d-dimer different category 0.1374 ratio indicating respiratory function significantly different critically ill patient compared patient severe 0.0025 moderate 0.0001 mild 0.0017 disease baseline observing lower ratio among critically ill patient table demographic baseline characteristic hospitalized patient covid-19 according disease severity category full size table table guideline clinical management covid-19 patient living guideline according may full size table table show different treatment regimen clinical outcome patient hospitalized covid-19 study period median iqr length hospital stay day 4.7–14.0 intensive care unit icu admission required 19.6 patient median iqr icu length stay 7.2 day 3.0–16.1 24.7 patient died icu hospital mortality occurred 18.9 patient seventy-five 17.7 20.1 patient died within day hospital admission respectively table treatment outcome hospitalized patient covid-19 full size table baseline antibody response limburg covid-19 cohort first analysed igm igg antibody response spike protein sars-cov-2 baseline within day positive pcr anti-spike protein antibody igm igg isotype detected 209/391 53.5 99/411 24.1 patient respectively subgroup patient presence igm igg antibody determined almost patient 181/182 negative igm isotype antibody also negative igg patient positive igm almost 91/92 patient tested positive igg also positive igm reflecting natural course response sars-cov-2 spike protein table next assessed whether log -transformed antibody level differed according disease severity sars-cov-2 specific igm level patient within severe disease category 0.0001 critically ill patient 0.0271 significantly higher patient belonging asymptomatic/mild subgroup fig igg antibody directed sars-cov-2 protein found overall trend towards higher igg antibody level patient belonging severe disease category statistically significant difference patient belonging moderate asymptomatic/mild subgroup 0.0020 fig table association igm igg seropositivity baseline full size table figure antibody level covid-19 patient according disease severity comparison log -transformed plasma serum level igm asymptomatic/mild moderate severe iii critically ill patient igg level asymptomatic/mild moderate severe iii critically-ill patient box plot visualizes following summary statistic middle line represents median lower hinge corresponds first quartile 25th upper hinge corresponds third quartile 75th upper lower whisker extend hinge respectively largest value smallest value data shown median range plus sign indicates average level significance calculated group value adjusted multiple comparison using tuckey-kramer method 0.05 full size image association baseline antibody level clinical outcome parameter association antibody level clinical outcome parameter analyzed using adjusted gee model gee model adjusted important covariates backward selection procedure including sex age bmi comorbidities therapy estimated based gee model hospital mortality lower patient higher level igm igg baseline tenfold increase baseline igm level corresponding 1-unit increase log -transformed scale odds hospital mortality decreased 0.73 0.68–0.79 0.0001 fig tenfold increase igg level decreased odds hospital mortality 0.57 0.45–0.71 0.0001 fig line observation adjusted model also showed lower odds mortality within day hospitalization increased level igm igg fig icu patient tenfold increase igm level associated lower odds icu mortality 0.53 0.34–0.83 0.005 fig significant association found igm igg antibody level odds admitted icu igg level odds icu mortality fig figure association baseline antibody level clinical outcome odds ratio shown association igm igg level clinical outcome including hospital mortality 30-day mortality 90-day mortality icu admission icu mortality using forest plot indicated table calculated using adjusted gee model model adjusted backward model selection procedure including sex age bmi comorbidities therapy line show confidence interval number patient included analysis p-value significant value lower level significance set indicated bold full size image association baseline antibody level laboratory parameter increased level anti-sars-cov-2 igg igm positively associated known soluble marker inflammation including crp d-dimers ferritin white blood cell count parameter estimate found fig considering log scale antibody level natural log scale parameter estimate inflammatory variable tenfold increase igm level associated increase geometric mean crp 0.001 ferritin 0.001 level factor 1.2 moreover tenfold higher igg level associated increase geometric mean d-dimers 0.001 significant association found igm igg antibody level ratio figure association baseline antibody level laboratory parameter result shown parameter estimate show average increase/decrease natural log scale corresponding marker one unit increase log10 scale igm igg antibody level using forest plot factor indicates change original scale one unit increase log10 scale igm/igg antibody level parameter estimate calculated using adjusted gee model model adjusted backward model selection procedure including age sex bmi comorbidities therapy line show confidence interval number patient included analysis p-value significant value lower level significance set indicated bold full size image baseline cytokine response limburg covid-19 cohort cytokine profile measured covid-19 patient serum concentration pro-inflammatory mediator tnfα il-1β detection limit half measured sample therefore excluded analysis serum level pro-inflammatory cytokine il-6 ip-10 anti-inflammatory cytokine il-10 showed stepwise increase according disease severity fig il-8 stepwise increase observed patient moderate towards critically ill subgroup fig remarkably cohort level pro-inflammatory cytokine gm-csf showed decrease critically ill patient compared asymptomatic/mild patient 0.0003 il-12 found statistically different level patient moderate disease compared asymptomatic 0.0011 critically ill group 0.0419 observing higher level patient moderate disease compared asymptomatic critically ill patient serum level type interferon cytokine ifnα2 ifnβ type interferon cytokine ifn-γ also increased severe covid-19 interestingly level ifn-λ2,3 significantly lower critically ill patient compared patient moderate 0.0001 severe disease 0.0001 whereas ifn-λ1 level progressively increased according disease severity figure cytokine level covid-19 patient according disease severity cytokine expression level replicates per sample measured serum using legendplex asymptomatic/mild moderate severe critically-ill group box plot visualizes following summary statistic middle line represents median lower hinge corresponds first quartile 25th upper hinge corresponds third quartile 75th upper lower whisker extend hinge respectively largest value smallest value data shown median range diamond indicates average level significance calculated group value adjusted multiple comparison using tuckey-kramer method 0.05 full size image association baseline cytokine level clinical outcome parameter increased baseline level cytokine il-8 il-6 ip-10 il-10 ifn-α ifn-β ifn-γ ifn-λ1 showed statistically significant positive association hospital mortality fig among pro-inflammatory cytokine il-6 23.47 12.75–43.22 0.0001 anti-inflammatory cytokine il-10 22.09 7.77–62.73 0.0001 showed highest increased odds hospital mortality tenfold increase baseline cytokine level although tenfold increase baseline ifn-λ1 level also resulted increase odds hospital mortality 7.65 1.62–36.09 0.0101 increasing ifn-λ2,3 level baseline associated lower odds hospital mortality specifically tenfold increase ifn-λ2,3 level odds hospital mortality decreased 29.3 0.71 0.52–0.97 0.0294 cytokine similar result obtained considering 30-day mortality fig 90-day mortality fig clinical endpoint measurement furthermore found increased level il-8 il-6 ip-10 il-10 ifn-β ifn-γ ifn-λ1 associated increased odds icu admission fig highest found il-6 14.48 5.71–36.73 0.0001 ifn-λ1 12.6 2.8–56.1 0.0009 hand increased level ifn-λ2,3 associated decreased odds icu admission 0.68 0.55–0.86 0.001 subset icu patient association pro-inflammatory cytokine il-6 il-8 ip-10 anti-inflammatory cytokine il-10 level icu mortality fig comparable association hospital mortality entire limburg covid-19 cohort majority association significant icu mortality significantly associated ifn-λ1 resulting higher icu mortality patient higher level ifn-λ1 20.27 2.49–164.76 0.0049 increased level ifn-λ2,3 0.67 0.49–0.92 0.0118 ifn-β 0.51 0.33–0.78 0.0022 level associated decrease odds icu mortality fig figure association baseline cytokine level clinical outcome odds ratio shown association cytokine level clinical outcome including hospital mortality 30-day mortality 90-day mortality icu admission icu mortality using forest plot indicated table calculated using adjusted gee model model adjusted backward model selection procedure including sex age bmi comorbidities therapy indicated table shown adjustment sex age bmi comorbidities therapy line show confidence interval number patient included analysis p-value significant value lower level significance set indicated bold full size image association baseline cytokine level laboratory parameter association measured serum cytokine inflammatory marker crp d-dimers ferritin white blood-cell count clinical severity marker ratio baseline assessed shown fig serum cytokine positively associated crp fig significant association il-6 0.0001 ip-10 0.0001 il-10 0.0001 ifn-α 0.0385 ifn-β 0.0001 ifn-γ 0.0001 ifn-λ1 0.0002 strongest association found il-6 ip-10 tenfold increase cytokine level resulted fourfold increase geometric mean crp level significant positive association found il-8 0.0468 ifn-λ2,3 0.0217 d-dimers whereas ifn-α 0.0022 ifn-λ1 0.0133 showed negative association fig furthermore significant positive association found il-6 0.0455 ip-10 0.0001 il-10 0.048 ifn-β 0.0001 ifn-γ 0.0001 ifn-λ1 0.0001 ifn-λ2,3 0.0001 ferritin level fig serum cytokine il-6 0.0001 il-10 0.0132 ifn-β 0.0003 positively associated white blood cell count whereas gm-csf 0.0371 ip-10 0.0002 ifn-α 0.0001 ifn-γ 0.0065 negatively associated fig negative association found il-8 0.0001 il-6 0.0001 ip-10 0.0004 il-10 0.0001 level ratio pronounced effect il-10 tenfold increase il-10 level resulted decrease geometric mean ratio fig contrast increasing il-12 0.0095 ifn-α 0.0265 level positively associated ratio figure association baseline cytokine level laboratory parameter result shown parameter estimate show average increase/decrease natural log scale crp d-dimer ferritin white blood cell count ratio one unit increase log10 scale cytokine level using forest plot factor indicates change original scale one unit increase log10 scale cytokine level parameter estimate calculated using adjusted gee model model adjusted backward model selection procedure including age sex bmi comorbidities therapy line show confidence interval number patient included analysis full size image discussion multi-centre cohort study characterized antibody cytokine response plasma serum sample respectively hospitalised covid-19 patient obtained first wave covid-19 pandemic belgium measured antibody cytokine level linked several clinical outcome parameter including hospital mortality 30-day 90-day mortality icu admission icu mortality different laboratory parameter study shown baseline anti-spike protein igm igg antibody increased according disease severity associated decreased odds hospital mortality furthermore showed pro-inflammatory cytokine il-8 il-6 ip-10 anti-inflammatory cytokine il-10 anti-viral cytokine ifn-α ifn-β ifn-γ ifn-λ1 baseline positively associated hospital mortality whereas higher ifn-λ2,3 level suggested protective hospital mortality previous study increasing age male sex certain comorbidities recognized risk factor poor outcome covid-19 cohort covid-19 pcr-confirmed positive patient found men often severely affected covid-19 woman stage disease furthermore obesity observed major risk factor adverse outcome linear correlation bmi admission icu also observed increase bmi moderately severely critically ill patient compared asymptomatic/mild patient analyzing laboratory parameter cohort found raised level crp ferritin d-dimers according disease severity line previous finding already showed association inflammatory marker covid-19 severity progression although antibody critical control protection viral infection influenza involvement antibody sars-cov-2 clearance modulation covid-19 disease severity remains precisely defined general patient infected sars-cov-2 generate virus-specific igm igg iga antibody peaking week post-symptom onset limburg covid-19 cohort anti-spike protein antibody igm igg isotype detected baseline respectively 53.5 24.1 patient considering timing igm igg production natural course infection indicates half cohort baseline sample taken early initial infection onset detectable igm response similarly finding also suggest quarter included patient already formed igg antibody hospitalized week sars-cov-2 infection currently available literature strongly suggests intensity igm igg antibody response associated clinical severity covid-19 patient cohort corroborate finding baseline level anti-spike igm igg higher patient severe disease moreover baseline antibody response also associated several inflammatory biomarkers host response level crp ferritin d-dimers far completely clear antibody level correlate covid-19 severity however baseline anti-spike antibody level associated level inflammatory biomarkers likely reflects general immune response already shown previously higher viral load stronger antibody response related severe disease status unfortunately cycle threshold value semi-quantitatively ass sars-cov-2 viral load recorded present cohort furthermore found frequency plasmablast dividing antibody-secreting cell increased according disease severity alternatively could suggested antibody-dependent enhancement ade phenomenon antibody strengthen virus entry replication play role covid-19 severity recently shown occur blood monocyte inducing inflammatory cell death possibly contributing excessive release pro-inflammatory cytokine contrast known association antibody response covid-19 severity association antibody response mortality covid-19 patient largely underreported respect found increased igm igg anti-spike antibody level baseline associated decreased odds hospital 30-day 90-day mortality indicating protective role anti-spike antibody mortality previous study small group critically ill patient already shown igg igm anti-spike antibody titre higher covid-19 patient survived compared pointing towards protective effect critically ill patient considering well-established association antibody level severity data support idea antibody response alone insufficient avoid severe disease course robust anti-spike antibody response essential survive line previous study found measured pro-inflammatory cytokine il-6 il-8 ip-10 higher patient severe covid-19 disease category baseline additionally associated increased odds mortality indeed reported il-6 il-8 ip-10 level associated increased severity poor outcome il-6 il-8 considered independent marker severe covid-19 upregulated inflammatory cytokine il-6 considered key cytokine involved cytokine storm triggered covid-19 given high level cytokine induced sars-cov-2 il-6 blocking agent used treating severe covid-19 far clinical study testing antagonist shown various effect patient covid-19 result meta-analysis indicate treatment tocilizumab humanized anti-il-6 receptor antibody reduces all-cause mortality day-28 little clinical improvement could observed furthermore multicentre open-label randomised controlled cov-aid trial clinical benefit observed upon blockade il-6 il-1 pathway early disease course hypoxic covid-19 patient evidence systemic cytokine release syndrome additionally reparixin il-8 receptor inhibitor currently tested clinical trial efficacy hospitalized adult patient moderate severe covid-19 pneumonia hand found increase il-10 level known anti-inflammatory effect associated increased mortality risk icu admission line previous study reporting il-10 level predict poor outcome patient covid-19 strong increase anti-inflammatory cytokine il-10 within cytokine storm considered secondary albeit counter regulatory response pro-inflammatory cytokine nevertheless must noted non-classical pro-inflammatory immunostimulatory effect il-10 found certain inflammatory condition covid-19 given ability il-10 induce cell activation cancer model il-10 level found correlate ifn-γ producing cd4 cd8 cell exhausted cell suggesting role il-10 cell exhaustion covid-19 remains unclear whether ifns protective detrimental effect covid-19 patient several study reported type iii ifn response patient severe covid-19 dampened early phase infection however study shown patient severe covid-19 robust type ifn response type ifn-α ifn-β type iii ifn-λ1 ifn-λ2,3 ifns share antiviral feature type ifns induce systemic pro-inflammatory response whereas type iii ifns suppress viral spread without causing inflammation study progressively higher level ifn-α2 ifn-β across severity spectrum asymptomatic/mild critically ill patient observed furthermore significant association found baseline ifn-α2 ifn-β level hospital mortality i.e odds ratio hospital mortality higher patient higher baseline ifn-α2 ifn-β level previously high level ifn-α reported strongly associated disease severity early time point day symptom onset associated longer hospital stay mortality remarkably investigating type iii ifn response ifn-λ1 level showed stepwise increase according disease severity whereas level ifn-λ2,3 significantly lower critically ill patient compared patient moderate severe disease furthermore study reveals opposite effect increased ifnλ1 ifnλ2,3 level hospital mortality current data regarding ifn-λ2,3 serum rather limited must noted significant decrease ifn-λ2,3 also observed serum sample severe covid-19 patient japan result together earlier mentioned unique biological property type iii ifns make attractive therapeutic agent covid-19 patient vitro study indeed demonstrate suppression sars‐cov‐2 replication mouse model pegylated human ifn-λ1 additionally sars‐cov‐2 rna expression decreased primary human airway epithelial cell pretreated ifn-λ1 currently clinical trial using pegylated ifn-λ1 covid-19 patient ongoing however first result single subcutaneous injection ifn-λ1 show significantly reduced time viral clearance resolution symptom compared placebo hand despite well-known antiviral effect type iii ifns recently shown ifn-λ disrupt lung epithelial barrier mouse leading worsened disease score increased susceptibility bacterial superinfection moreover bronchoalveolar lavage fluid severe covid-19 patient elevated mrna expression inflammatory cytokine well type iii ifns found high expression type iii ifns lung associated covid-19 disease morbidity furthermore ifn-λ also shown inhibit influenza virus-stimulated b-cell activation antibody production thereby suggesting negative effect adaptive immune response critical resolution infection understanding location timing duration probably critical parameter interferon response taken account ifn therapeutic strategy interestingly ifnλ1 ifnλ2 upregulated patient infected hepatitis virus remarkably vitro study ifn-λ2 ifn-λ1 act potent gene repressor latter one suggests possible explanation observed opposite effect increased ifn-λ1 ifn-λ2,3 level hospital mortality study needed find whether member ifn-λ family cause different effect covid-19 disease study several limitation potential source bias result may stem different timing sampling antibody cytokine covid-19 patient timing chosen day positive pcr antibody cytokine respectively onset symptom considered due unreliable often unavailable recording first wave covid-19 pandemic furthermore wide confidence interval associated need interpreted care issue likely result lower sample size certain subgroup conclusion data indicate baseline anti-spike igm igg level associated clinical severity associated decreased odds hospital mortality furthermore baseline level pro-inflammatory cytokine il-8 il-6 ip-10 anti-inflammatory cytokine il-10 anti-viral cytokine ifn-α ifn-β ifn-γ ifn-λ1 positively associated mortality whereas higher ifn-λ2,3 level suggested protective mortality material method study design patient retrospective cross-sectional study performed using plasma serum sample hospitalized covid-19 patient confirmed nasopharyngeal swab pcr diagnosis hospital sample collected different hospital ziekenhuis oost-limburg genk jessa hospital hasselt noorderhart hospital pelt algemeen ziekenhuis vesalius tongeren st-trudo hospital sint-truiden province limburg belgium first wave covid-19 march june referred limburg covid-19 cohort patient included cohort admitted july september human biological material used publication stored university biobank limburg ubilim prior analysis serum and/or plasma sample collected baseline within day positive pcr antibody detection within day positive pcr cytokine measurement demographic clinical laboratory parameter clinical outcome data hospitalized patient obtained medical record table demographic characteristic include age sex body mass index bmi laboratory parameter including level crp d-dimers ferritin white blood cell count respiratory parameter ratio ratio arterial oxygen partial pressure pao fractional inspired oxygen fio measured time baseline blood sampling clinical parameter include presence comorbidities medical record arterial hypertension diabetes kidney injury malignancy lung disease heart failure hepatic failure immunocompromised status use therapy antibacterial therapy antiviral medication including lopinavir remdesivir antifungal therapy anti-inflammatory therapy including interleukin inhibitor corticosteroid hydroxychloroquine renal replacement therapy vasopressor use therapy clinical outcome data including in-hospital mortality all-cause mortality hospital stay 30-day mortality all-cause mortality within day hospital admission 90-day mortality all-cause mortality within day hospital admission intensive care unit icu admission icu mortality evaluated course hospitalisation patient follow time baseline blood sampling patient classified severity category table based clinical characteristic according clinical management covid-19 interim guidance issued may documented approval obtained institutional medical ethic committee central positive advice granted commission medical ethic uhasselt cme2020/040 ziekenhuis oost-limburg 20/0058r according belgian act december usage human body material scientific research part 1–2 5–20 informed consent needed retrospective study method carried accordance belgian act december retrospective study antibody detection igm antibody receptor binding domain rbd subunit sars-cov-2 spike protein igg antibody subunit sars-cov-2 spike protein detected serum plasma sample using enzyme linked immunosorbent assay elisa igm beijing wantai biological igg euroimmun according manufacturer instruction sample considered seropositive according cut-off respective elisa kit igg igm antibody level quantified linear interpolation using serial dilution positive plasma sample later converted arbitrary unit using anti-sars-cov-2 antibody diagnostic calibrant 20/162 national institute biological standard control nibsc united kingdom cytokine analysis circulating serum level cytokine measured legendplex human anti-virus response panel 13-plex biolegend san diego usa according manufacturer instruction minor adjustment include cytokine tnf-α il-1β il-8 il-6 ip-10 gm-csf il-12 ifn-α ifn-β ifn-γ ifn-λ1 ifn-λ2,3 il-10 assay carried v-bottom 96-well plate serum 12.5 thawed diluted twofold assay buffer testing standard mixed bead detection antibody streptavidin-pe prepared according manufacturer instruction 12.5 reagent used serum sample tested duplicate data collected using lsrfortessa flow cytometer bioscience analysed using legendplex™ data analysis software suite biolegend value assay lower limit detection value detection limit used average cytokine level calculated duplicate measurement statistical analysis descriptive statistic continuous patient demographic clinical characteristic clinical outcome reported median interquartile range iqr discrete characteristic outcome summarized count percentage examine difference continuous patient demographic according disease severity data normally distributed aligned rank transform applied data difference discrete patient demographic according disease severity examined using generalized estimating equation gee model aforementioned method correct correlated nature data patient clustered within hospital p-values corrected multiple comparison according tukey–kramer method order examine effect antibody cytokine response baseline disease severity gee model applied considers correlation response patient hospital analysis antibody cytokine level log -transformed comparison level disease severity category asymptomatic/mild moderate severe made using patient critically ill disease baseline reference group association antibody cytokine level clinical outcome investigated using gee model accounting correlation data analysis antibody cytokine level log -transformed continuous outcome measure natural logarithmic transformation used backward model selection procedure performed using patient age sex bmi comorbidities therapy clinical outcome parameter final model includes significant parameter term related antibody cytokine level referred adjusted model following covariates included backward model selection procedure age bmi sex diabetes arterial hypertension kidney injury lung disease malignancy immune status antibacterial therapy ever corticosteroid therapy ever hydroxychloroquine therapy ever manuscript focus result interpretation related cytokine antibody level included adjusted model however information significant covariates included adjusted model available supplementary file studying association cytokine icu admission icu mortality adjusted model used including age sex covariates addition term related antibody cytokine level model selection carried since model model selection procedure would converge due small number patient admitted icu binary outcome measure result adjusted gee model presented odds ratio one-unit increase log antibody cytokine level continuous outcome measure result presented average denoted parameter estimate representing increase decrease outcome measure one-unit increase log antibody cytokine level alternatively result adjusted gee model laboratory parameter also presented factor representing fold change geometric mean outcome due back-transformation natural logarithm tenfold increase cytokine antibody level tenfold increase original scale corresponds one-unit increase log scale confidence interval p-value parameter estimate tabulated 0.05 deemed statistically significant analysis performed assume missing data missing completely random supplementary information statistical analysis performed using software window version 9.4 copyright ©2016 version 4.1.2